<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01491347</url>
  </required_header>
  <id_info>
    <org_study_id>2011-A00452-39</org_study_id>
    <nct_id>NCT01491347</nct_id>
  </id_info>
  <brief_title>Brain Derived Neurotrophic Factor Serum Levels Evolution During the Six Months After Alcohol Withdrawal</brief_title>
  <official_title>Brain Derived Neurotrophic Factor Serum Levels Evolution During the Six Months Following After Alcohol Withdrawal in Alcohol-dependent Subjects in Relation to Abstinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Esquirol</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Esquirol</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alcohol dependence is accompanied by several neurological mechanisms involving neuronal&#xD;
      plasticity and neoneurogenesis, requiring Brain Derived Neurotrophic factor (BDNF) synthesis.&#xD;
&#xD;
      The investigators found that serum BDNF levels in alcohol-dependent subjects increased to a&#xD;
      greater extent in subjects who had remained abstinent at 6 months after withdrawal than in&#xD;
      subjects who had relapse.&#xD;
&#xD;
      To verify if the BDNF serum levels variation is linked to the way that abstinence is&#xD;
      installed, wthe investigators will measure BDNF serum levels in alcohol dependent subjects at&#xD;
      the moment of withdrawal, and 14, 28 days, and 2, 4, and 6 months after to establish its&#xD;
      evolution in relation to alcohol consumption, and other clinical characteristics : depression&#xD;
      intensity, anxiety, alcohol craving, biological markers of alcohol consumption or toxicity.&#xD;
      Monitoring serum BDNF concentrations in link with other clinical data could help to&#xD;
      characterize alcohol dependence profiles in clinical practice, help predict relapses, and&#xD;
      assist in adjusting care to prevent difficulties in alcohol withdrawal.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 205 patients will be recruited at their hospitalization time for alcohol&#xD;
      withdrawal during a 18 months period. The follow-up at 14, 28 days, 2, 4, 6 months after&#xD;
      alcohol withdrawal will assess their BDNF serum levels, the levels of carbohydrate deficient&#xD;
      transferrin (CDT), gamma glutamyl transferase (GGT), urinary ethylglucuronide (EtG), and the&#xD;
      scores to the Beck Depression Inventory (BDI), the Montgomery Asberg depression scale&#xD;
      (MADRS), the Hamilton'anxiety scale (HAM-A), the Obsessive Compulsive Drinking Scale (OCDS).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>BDNF serum levels variations between alcohol withdrawal and 14-, 28- days, 2-, 4- and 6- months after in relation to abstinence at 6 months.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Search of a correlation between serum BDNF levels and alcohol consumption marker (CDT), GGT, EtG at 28 days 2, 4, and 6 months after alcohol withdrawal.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Search of a correlation between serum BDNF levels and the scores to psychometric scales : BDI, MADRS, HAM-A, OCDS, at 28 days 2, 4, and 6 months after alcohol withdrawal.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">389</enrollment>
  <condition>Alcohol Dependence</condition>
  <arm_group>
    <arm_group_label>alcohol dependent</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with alcohol dependance diagnosis according to the Diagnostic and Statistical&#xD;
        Manual of Mental Disorders (DSM-IV-TR), and asking for alcohol withdrawal in&#xD;
        hospitalization&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of alcohol dependence according to the DSM-IV-TR&#xD;
&#xD;
          -  Request for withdrawal&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  Psychiatric co-morbidity in an evoluting stage and predominant on the addiction&#xD;
             trouble&#xD;
&#xD;
          -  Characterized (diagnosed) neurological co-morbidity&#xD;
&#xD;
          -  Severe somatic pathology and / or with fatal predicted outcome in the year (cancer...)&#xD;
&#xD;
          -  Inability to answer the questionnaires&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  neuroleptic or antidepressant treatment established for less than 3 months&#xD;
&#xD;
          -  anti-retroviral treatment&#xD;
&#xD;
          -  absence of consent, judiciary protection, hospitalization under constraint, - absence&#xD;
             of health insurance.&#xD;
&#xD;
          -  Residence at more than 80 km from the study center&#xD;
&#xD;
          -  Participation to an other biomedical study during the 6 months of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Nubukpo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Esquirol</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinique Saint Maurice</name>
      <address>
        <city>La Jonch√®re</city>
        <zip>87340</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Esquirol</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Vauclaire</name>
      <address>
        <city>Montpon Menesterol</city>
        <zip>24700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier La Vallette</name>
      <address>
        <city>Saint-Vaury</city>
        <zip>23300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Costa MA, Girard M, Dalmay F, Malauzat D. Brain-derived neurotrophic factor serum levels in alcohol-dependent subjects 6 months after alcohol withdrawal. Alcohol Clin Exp Res. 2011 Nov;35(11):1966-73. doi: 10.1111/j.1530-0277.2011.01548.x. Epub 2011 Aug 16.</citation>
    <PMID>21848960</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>December 12, 2011</study_first_submitted>
  <study_first_submitted_qc>December 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2011</study_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Esquirol</investigator_affiliation>
    <investigator_full_name>Philippe Nubukpo</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>BDNF</keyword>
  <keyword>withdrawal</keyword>
  <keyword>alcohol</keyword>
  <keyword>psychiatry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

